Survodutide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Oct 2023: Trial registered, NCT06066528
  2. 27 Nov 2023: Trial started, NCT06066528

The trials

NCT06066528: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

State
Completed
Phase
Phase 3
People
755 taking part
Started
27 Nov 2023
Primary completion
12 Dec 2025
Arms
Survodutide 3.6 mg, Survodutide 6.0 mg
Results
None posted
Papers
doi:10.1056/nejmoa2607219, doi:10.1111/dom.70263
  1. 4 Oct 2023: Trial registered
  2. 27 Nov 2023: Trial started
  3. 1 Apr 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as BI 456906, Survodutide formulation A, Survodutide formulation B2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.